Eos Energy Enterprises Inc vs Medpace Holdings Inc — how do they compare? Eos Energy Enterprises Inc trades at $2.56 (market cap $1.01B), while Medpace Holdings Inc trades at $617.47 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 16.7× Eos Energy Enterprises Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 16 Days and Medpace Holdings Inc for 14 Days on average.
| EOSE | MEDP | |
|---|---|---|
Market Cap | $1.01B | $16.82B |
Volume | 39,626,541 | 223,093 |
Sector | Industrials | Health |
52-Week High | $19.19 | $630.19 |
52-Week Low | $2.77 | $393.42 |
Typical Hold Time | 16 Days | 14 Days |
Enterprise Value | $1.34B | $16.44B |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $2.645, down 14.68% in the last session, reflecting significant volatility amid mixed quarterly results. The company shows rapid revenue growth but deep losses, with a -246.76% net income margin in 2026. Recent developments include a $87 million DOE loan advance and a partnership with Google for a West Virginia energy project, highlighting growth potential in long-duration energy storage.
The outlook is bifurcated: strong revenue growth and strategic partnerships offer upside, but persistent losses and high debt-to-asset ratio of 91.87% pose substantial risks. Analyst consensus is cautious with a $7.10 price target, suggesting 168% potential upside, yet the bearish technical signal and negative cash flows from operations warrant careful monitoring of execution and funding needs.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →